This is an international site for Sandostatin® LAR® and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Sandostatin LAR Information for US residents Sandostatin LAR Information for International Healthcare Professionals Sandostatin LAR Information for Patients Outside the US
Sandostatin® LAR® Delivers Powerful Efficacy and Unparalleled Evidence

Home > Resources > Published Data > Acromegaly

Published Data

Stay current on information about acromegaly, NETs, and carcinoid syndrome and the clinical use of Sandostatin® for treating these conditions. Review the latest research papers and journal articles online and view clinical slide presentations on the following topics:

NETs

The abstract for each article can be viewed free of charge, or you can access the full article by visiting http://www.ncbi.nlm.nih.gov/PubMed/.
*Note: you may be required to purchase the full article from PubMed.

Links on this site lead to resources located on servers maintained by third parties over whom Novartis has no control. As such, Novartis makes no representation as to the accuracy or any other aspect of the information contained on such servers. Please note that some of the indications listed below are not approved for Sandostatin® LAR® and should be considered investigational. For approved indications, please see your local product information.

Acromegaly

Murray R.D., Melmed S.
A Critical Analysis of Clinically Available Somatostatin Analog Formulations
for Therapy of Acromegaly. J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68. Epub 2008 May 13.
http://www.ncbi.nlm.nih.gov/pubmed/18477663?ordinalpos=2&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Carlsen S.M., Lund-Johansen M., Schreiner T., Aanderud S., Johannesen O., Svartberg J., Cooper J.G., Hald J.K., Fougner S.L., Bollerslev J.; on behalf of the POTA study group.
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008 Aug;93(8):2984-2990. Epub 2008 May 20.
http://www.ncbi.nlm.nih.gov/pubmed/18492760?ordinalpos=4&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Colao A., Pivonello R., Auriemma R.S., Galdiero M., Savastano S., Grasso L.F., Lombardi G.
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-LAR therapy predicts the response at 12 months.
J Clin Endocrinol Metab. 2008 Jul 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/18593770?ordinalpos=7&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Colao A., Pivonello R., Galderisi M., Cappabianca P., Auriemma R.S., Galdiero M., Cavallo L.M., Esposito F., Lombardi G.
Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. J Clin Endocrinol Metab. 2008 Jul;93(7):2639-46. Epub 2008 Apr 29.
http://www.ncbi.nlm.nih.gov/pubmed/18445662?ordinalpos=14&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Colao A., Marek J., Goth M.I., Caron P., Kuhn J.M., Minuto F.M., Weissman N.J.
No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008 Jun;93(6):2243-8. Epub 2008 Apr 1.
http://www.ncbi.nlm.nih.gov/pubmed/18381583?ordinalpos=22&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Holdaway I., Bolland M., Gamble G.
 A meta-analysis of the effect of lowering serum levels of growth hormone and insulin-like growth-factor-I on mortality in acromegaly. Eur J Endocrinol. 2008 Jun 4. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/18524797?ordinalpos=1&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Colao A.
The GH/IGF axis and the cardiovascular system: clinical implications.
Clin Endocrinol (Oxf). 2008 May 6. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/18462260?ordinalpos=13&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, Degli Uberti EC.
GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf). 2008
Apr 10. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/18410555?ordinalpos=17&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Bolanowski M., Bar-Andziak E., Kos-Kudła B., Krzyzanowska-Swiniarska B., Lewiński A., Łomna-Bogdanov E., Milewicz A., Sowiński J., Zgliczyński W.; Polish Society for Endocrinology.
Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly. Neuro Endocrinol Lett. 2008 Feb;29(1):59-62.
http://www.ncbi.nlm.nih.gov/pubmed/18283267?ordinalpos=8&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Back to top